February 11, 2015
Unlike in other areas of oncologic focus, the role of the nuclear medicine physician in a multidisciplinary team for the management of prostate cancer disease had been largely confined to imaging; this was due to the lack of efficacy of radio-metabolic therapies to impact the progression of disease, and ultimately, survival.
An exception may be the opportunity to treat, with β-emitting-radiopharmaceuticals, patients presenting with bone metastases due to castration resistant prostate cancer. These radio-drugs were approved by health authorities with the goal of relieving bone metastases pain without any curative purpose. Radionuclides used as single arm, did not significantly demonstrate prolonged survival and were associated with important hematologic adverse events. Therefore the use of beta-emitting radiopharmaceuticals was mostly limited to the treatment of patients presenting with terminal disease stage.